Cory Renauer
Value, research analyst, biotech, small-cap

Why Ariad's Iclusig Is A Potential Blockbuster

While trying to explain exactly why the cancer medicine Iclusig (ponatinib) is a real breakthrough for Ariad Pharmaceuticals (NASDAQ:ARIA) I realized that I needed to provide a bit of background first. Some will find the quick biology lesson below too detailed, others too not detailed enough. I'll happily answer questions in the comments section below.

Chronic myeloid leukemia [CML] is characterized by the unregulated growth of myeloid cells in the bone marrow, which then find their way into the bloodstream. Without getting too detailed, the reason that the myeloid cells grow unchecked is due in large part to out-of-control tyrosine kinases.

In normal cells, tyrosine kinases behave like a button pusher that turns on other proteins that carry...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details